Clinical Trials · NCT02294006
Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Enrollment
- 26
- Start date
- Jun 2014
- Locations
- 1 site, Italy
- Primary endpoint
- to determine the progression free survival rate (PFS) at 12 months from the first drug administration in patients with advanced pancreatic neuroendocrine tumors